1. Home
  2. CCSI vs ALT Comparison

CCSI vs ALT Comparison

Compare CCSI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

HOLD

Current Price

$37.46

Market Cap

493.6M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.99

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCSI
ALT
Founded
2021
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.6M
421.5M
IPO Year
2022
2005

Fundamental Metrics

Financial Performance
Metric
CCSI
ALT
Price
$37.46
$2.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$37.50
$17.67
AVG Volume (30 Days)
141.0K
4.6M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
1.30
N/A
Revenue
$349,696,000.00
$41,000.00
Revenue This Year
$3.33
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
$29.51
N/A
Revenue Growth
N/A
105.00
52 Week Low
$19.42
$2.56
52 Week High
$41.40
$6.44

Technical Indicators

Market Signals
Indicator
CCSI
ALT
Relative Strength Index (RSI) 60.22 51.75
Support Level $35.92 $2.62
Resistance Level $41.40 $3.15
Average True Range (ATR) 1.82 0.17
MACD -0.13 -0.00
Stochastic Oscillator 42.65 37.88

Price Performance

Historical Comparison
CCSI
ALT

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: